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Abstract
Background
The search for a SARS-CoV-2 treatment has emerged as a worldwide priority. We evalu-
ated the role of chloroquine and its derivatives in COVID-19 in Spanish individuals.
Methods
We performed a survey addressed to patients regularly taking chloroquine and its deriva-
tives for the control of their autoimmune diseases. The survey was distributed with special
attention to Spanish patient associations centred on autoimmune diseases and rheumatol-
ogy and to the general population. A sample of untreated subjects was matched to the
treated group according to sex, age range and incidence region. COVID-19 disease preva-
lence was compared between treated and untreated-matched control sample.
Results
A total of 319 surveys of patients regularly taking chloroquine and its derivatives were recov-
ered for further analysis. The prevalence of declared COVID-19 status in the treated group
was 5.3% and the mean prevalence among the untreated-matched groups was 3.4%. A
community exposition to COVID-19 was associated with a greater prevalence of COVID-19
in both, treated (17.0% vs. 3.2%; p-value<0.001) and untreated groups (13.4% vs. 1.1%; p-
value = 0.027).
Conclusion
We did not find differences of reported COVID-19 cases between treated and untreated
groups, indicating a lack of protection by regular administration of chloroquine and its deriva-
tive drugs on COVID-19 infection. Of relevance, data indicates that patients that regularly
take chloroquine derivatives are exposed to SARS-CoV-2 infection and must take the same
protection measures as the general population.
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Introduction
The search for an effective treatment against SARS-CoV-2 infection has emerged as a world-
wide priority. A promising strategy to fight the virus causing the newest pandemic is the iden-
tification of already available drugs active against other diseases that can be effective also
against this new SARS-CoV-2 infection [1].
We present here an evaluation of the potential protective effect of chloroquine and its
derived drugs on the prevalence of COVID-19 in patients undergoing an active treatment with
these drugs.
Chloroquine and its derived drugs such as hydroxychloroquine have shown in vitro and in
vivo effectiveness against viral infections such as SARS [2], influenza A H5N1, and Zika. Chlo-
roquine is believed to interfere with both the entry and exit of viruses from cells hosts, as well
as in the manifestation of acute respiratory syndrome. The virus enters the cells through bind-
ing to the angiotensin-converting enzyme 2 (ACE2). Chloroquine can reduce ACE2 glycosyla-
tion, thereby preventing viruses from effectively binding to cells [3]. On the other hand,
chloroquine accumulates in lysosomes, increasing the endosome pH levels which interferes
with the viral particle release process [4]. In addition, chloroquine could block the production
of proinflammatory cytokines, thus preventing the pathway that subsequently leads to acute
respiratory syndrome [5]. Two recent clinical trials have presented inconclusive evidence on
the effectiveness of chloroquine treatment in COVID-19 disease in Chinese [6] and French [7]
populations. Both studies have supported the use of chloroquine or chloroquine derivatives
against COVID-19, however, the design and conclusions of both studies have been questioned
[8].
Chloroquine and its derivatives such as chloroquine phosphate or hydroxychloroquine are
commonly used in the treatment of autoimmune diseases. Not without serious side effects, the
use of these drugs under medical prescription is widely spread. It has been proposed hydroxy-
chloroquine as a prophylaxis treatment against SARS-CoV-2 infection for exposed caregivers
[9–11]. Our hypothesis is that if chloroquine treatment is effective against SARS-CoV-2 infec-
tion, those patients following an active chloroquine or derivative drug treatment would be pro-
tected against the infection or against COVID-19 adverse effects. Thus, our study aims to test
this hypothesis by evaluating the incidence of COVID-19 disease in the population according
to chloroquine treatment subgroups through a survey.
Material and methods
Survey design and data collection
A survey was distributed in Spanish and Catalan languages and conceived to be conducted
electronically via smartphone or personal computer, and therefore it was also designed to
ensure accessibility and simplicity to facilitate its completion. A copy of the original survey in
Spanish and Catalan languages and a translated English version can be found as S1–S3 Texts.
Information about the project and a link to the URL of the survey were disseminated in the
press and via social media and email, with special attention to Spanish patient associations cen-
tered on autoimmune diseases and rheumatology. The survey included demographic questions
about gender, age range, and Autonomous Community of residence, as well as questions per-
taining to health-status outcomes such as treatment, COVID-19 diagnosis and symptoms due
to COVID-19 infection. In addition, questions about infection diagnosis and symptoms in
close relatives and friends were also included. Because the first cases of COVID-19 were
reported in Spain in March 2020, our survey collects cases that occurred between March and
May 2020.
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In order to evaluate the effect of chloroquine and its derivatives on COVID-19 infection
risk, we have taken advantage of the unique available source of people receiving this drug as a
chronic treatment, the group of patients with autoimmune diseases. However, at time of
recruitment a very low percentage of COVID-19 patients had an autoimmune disease (less
than 1%) [12], while age, gender and region of origin were the main known factors affecting
SARS-CoV-2 infection in Spain’s autonomies. In addition, the recruitment of untreated cases
had to comprise a large number of individuals to be able to do the proper matching between
treated and untreated individuals, being the treated patients the limiting group. According to
this, we decided to use individuals from the general population as untreated cases considering
age, gender and Autonomous Community of residence as the main selection criteria for
recruitment.
Individuals of any age above legal age (18 years old) with residence in Spain were eligible
for inclusion in the study. Individuals undergoing a stable chloroquine or derived drug treat-
ment before the COVID-19 pandemic were classified as treated (treated group) while individ-
uals without treatment and those beginning acute treatment in the last three months (January-
March) were classified as untreated (untreated group). Individuals beginning acute treatment
were receiving it as a treatment after being infected with SARS-CoV-2, thus, they were not
under treatment prior to infection.
The Clinical Research Ethics Committee of the Hospital Universitari Arnau de Vilanova in
Lleida approved the study (Ref: CEIC-2257).
Statistical analysis
Statistical analyses were performed with R software (v3.6.0) and IBM SPSS v21 (IBM corpora-
tion, NY, USA). Prior to the analysis, reported autonomy of residence in Spain were grouped
according to COVID-19 incidence as stated in June 1 by the Spanish Ministry of Health [13]
as follows: Incidence region 1 (incidence<200/100,000 inhabitants) that includes Andalucı́a,
Canarias, Ceuta, Illes Balears, Melilla and Región de Murcia; Incidence region 2 (incidence
200-500/100,000 inhabitants) that includes Aragón, Cantabria, Comunidad Valenciana, Extre-
madura, Galicia and Principado de Asturias; Incidence region 3 (incidence 500–1,000/100,000
inhabitants) that includes Castilla y León, Castilla-La Mancha, Catalunya, Euskadi and
Navarra; and Incidence region 4 (incidence>1,000/100,000 inhabitants) that includes Comu-
nidad de Madrid and La Rioja. Age categories were assigned according to the following age
ranges: 18–50, 51–65 and>65 years old. Data on symptoms related to COVID-19 infection
were collected and used to assign individuals as suspected COVID-19 cases when reporting
loss of taste or smell and/or three or more COVID-19 associated symptoms [14].
A sample of untreated subjects was matched to the treated group according to sex, age
range and incidence region with e1071 R package. The matching process was repeated using a
bootstrap strategy and re-sampling of the untreated-matched dataset was repeated 1,000 times
to obtain the distribution and mean values of the descriptive statistics such as age range, gen-
der, incidence region and declared COVID-19 prevalence. Statistical analysis was performed
to validate the appropriate distribution of the demographic characteristics within each group
what rules out the possibility of a bias towards one of the variables. In addition, tests between
treated and untreated groups were used to confirm the proper matching of the subjects. Com-
parisons were performed by Fisher exact test. P-value <0.05 was considered statistically signif-
icant. Comparison of differences among treated group and 1000 replicates of untreated-
matched groups was performed by Fisher exact test. In addition, the difference between the
two proportions and a 95% confidence interval for this difference was performed using the
comparison of proportions method (Chi-squared test).
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Results
Overall, 2295 individuals completed the surveys between May and June 2020. From these, data
collection was complete, with all key data for the study, for 2161 individuals (94.2%). These
completed surveys were checked for inconsistencies and possible duplicated values as well as
to fulfil the eligibility criteria, 11 entries were excluded from further analysis. The final number
of completed surveys used for the study was 2150. A copy of the anonymized data set is pro-
vided in S1 Data. Among them, 319 (14.8%) were from patients following an active chloro-
quine or derived drug treatment and have been included in the treatment group, and 1831
(85.2%) have been included in the untreated group and serves as the source to obtain the
untreated-matched subgroups. We note that 94% of the treatment group individuals were fol-
lowing a hydroxychloroquine treatment.
The main descriptive characteristics of both treated (n = 319) and untreated-matched
(n = 319) subgroups, arranged according to their declared COVID-19 status, are reported in
Table 1. Distribution of declared COVID-19 status did not differ significantly within age
group, gender and incidence region (Table 1). In contrast, having a community exposition
Table 1. Demographic characteristics of persons taking chloroquine or derivatives (treated) and matched control sample (untreated) according to their declared
COVID-19 status.
Treated (n = 319) Untreated (na = 319) Treated vs
Untreated
COVID-19 (+) COVID-19 (-) Totals P-value COVID-19 (+) COVID-19 (-) Totals P-value P-value
Age range, n (%)
18–50 9 (4.7) 182 (95.3) 191 0.433 6.7 (3.5) 185.4 (96.5) 192.2 0.999 0.981
51–65 8 (7.1) 105 (92.9) 113 3.9 (3.5) 107.5 (96.5) 111.3
> 65 0 (0.0) 15 (100.0) 15 0.3 (2.1) 15.2 (97.9) 15.5
Total 17 (5.3) 302 (94.7) 319 10.9 (3.4) 308.1 (96.6) 319
Sex, n (%)
Male 1 (4.8) 20 (95.2) 21 0.905 1.1 (5.0) 20.2 (95.0) 21.2 0.973 1.000
Female 16 (5.4) 282 (94.6) 298 9.8 (3.3) 287.9 (96.7) 297.8
Total 17 (5.3) 302 (94.7) 319 10.9 (3.4) 308.1 (96.6) 319
Incidence regionb, n (%)
R1 1 (2.4) 40 (97.6) 41 0.420 0.0 (0.0) 41.1 (100.0) 41.1 0.275 0.215
R2 1 (2.8) 35 (97.2) 36 1.0 (3.4) 28.7 (96.6) 29.7
R3 11 (5.4) 193 (94.6) 204 6.1 (2.7) 218.8 (97.3) 225.0
R4 4 (11.4) 31 (88.6) 35 3.2 (15.9) 17.0 (84.1) 20.2
Unknown 0 (0.0) 3 (100.0) 3 0.5 (17.3) 2.5 (82.7) 3.0
Total 17 (5.3) 302 (94.7) 319 10.9 (3.4) 308.1 (96.6) 319
Community exposition, n (%)
Exposedc 8 (17.0) 39 (83.0) 47 <0.001 8.2 (13.3) 53.3 (86.7) 61.5 0.027 0.300
Unexposed 7 (3.2) 210 (96.8) 217 2.2 (1.1) 204.4 (98.9) 206.6
Unknown 2 (3.6) 53 (96.4) 55 0.5 (1.0) 50.4 (99.0) 50.9
Total 17 (5.3) 302 (94.7) 319 10.9 (3.4) 308.1 (96.6) 319
COVID-19: disease caused by SARS-CoV-2 infection.
a Mean after 1000 replicates of matched untreated control samples.
b Regions grouped by incidence of COVID-19. IR1 (incidence <200/100,000 inhabitants) that includes Andalucı́a, Canarias, Ceuta, Illes Balears, Melilla and Región de
Murcia; IR2 (incidence 200-500/100,000 inhabitants) that includes Aragón, Cantabria, Comunidad Valenciana, Extremadura, Galicia and Principado de Asturias; IR3
(incidence 500–1,000/100,000 inhabitants) that includes Castilla y León, Castilla-La Mancha, Catalunya, Euskadi and Navarra; and IR4 (incidence >1,000/100,000
inhabitants) that includes Comunidad de Madrid and La Rioja.
c Exposed were those individuals declaring a COVID-19 positive case in a close family member or flatmate.
https://doi.org/10.1371/journal.pone.0243598.t001
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(defined as those individuals declaring a COVID-19 positive case in a close family member or
flatmate) was associated with a greater prevalence of COVID-19 disease when compared with
non-exposed individuals in both treated (17.0%, 95%CI 12.9%-21.1% vs. 3.2%, 95%CI 1.3%-
5.2%; p-value<0.001) and untreated subgroups (13.4%, 95%CI 9.6%-17.1% vs. 1.1%, 95%CI
0%-2.2%; p-value = 0.027) (Table 1 and Fig 1). Furthermore, we evaluated the distribution of
the descriptive characteristics between treated and untreated groups denoting no statistical sig-
nificant differences, and thus, confirming the appropriate matching of the groups (Table 1).
The prevalence of declared COVID-19 status in the treated group was 5.3% (95%CI 2.9–
7.8) and the mean prevalence among the untreated-matched groups was 3.4% (95%CI 1.4–
5.4). Testing differences among treated and 1000 replicates of untreated-matched groups
reveals significant differences only in 28 comparisons (P = 0.972). In addition, the difference
of proportions of declared COVID-19 cases between both groups did not reach statistical sig-
nificance (difference 1.9%, 95%CI: 0–5.3; P = 0.240). Furthermore, the prevalence of suspected
COVID-19 patients in treated subjects was of 18.8% (95%CI 14.5–23.1) and the mean preva-
lence among the untreated-matched groups was 15.7% (95%CI 11.7–19.7). Neither the com-
parison of the prevalence nor the distribution of the difference of declared COVID-19 cases
among groups showed significant differences. These figures are nearly similar to those recently
found in the study of the seroprevalence of IgG antibodies against SARS-CoV-2 in the Spanish
population showing an estimated prevalence of 5% (95%CI 4.7%-5.4%), and a prevalence of
suspected COVID-19 cases of nearly 20% [14].
Fig 1. Percentage of declared COVID-19 cases according to treatment status and community exposition. Treated group refers to
patients regularly taking chloroquine and its derivatives. Exposed are those individuals declaring a COVID-19 positive case in a close
family member or flatmate. Error bars depict the 95% confidence interval.
https://doi.org/10.1371/journal.pone.0243598.g001
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Discussion
Our results show no differences in COVID-19 prevalence among untreated and chronically
treated individuals with chloroquine or derivative drugs. Independently of the exposure, both
groups showed the same prevalence of COVID-19 disease or suspected COVID-19 disease
according to symptoms. We must note that we found a clear association between the COVID-
19 disease prevalence and exposure to a close family member or flatmate positive for COVID-
19 in both, treated and untreated subjects, that points to a lack of any protective effect on
SARS-CoV-2 infection attributable to chronic treatment with chloroquine or derivative drugs.
We should mention some limitations of our study such as a limited power to detect small
changes in prevalence between treatment groups. However, the design of this study addressed
the need to collect and analyse data within a particularly short period of time due to the rapid
onset and progression of the pandemic, as well as the urgency of identifying and evaluating
rapidly possible therapies, thus partially compensating the reduced sample size. The prevalence
of COVID-19 found in our study is similar to the seroprevalence of IgG antibodies against
SARS-CoV-2 in the Spanish population [14], which is higher than the reported COVID-19
prevalence in the general population based on RNA’s virus detection [13]. This difference
could be attributed to self-reported disease and the diagnosis of COVID-19 by medical practi-
tioners, which in many cases does not involve results of diagnostic tests due to the lack of such
tests. Finally, we could not eliminate completely the possibility of some bias due to the intrinsic
condition of the individuals within the treatment group that are undergoing chloroquine or
derivative drug treatment due to other diseases that alter their health status and may have dif-
ferent comorbidities. A previous study reported a low portion of autoimmune diseases patients
as COVID-19 cases (less than 1%) [12]. On the other hand, the main factors reported to affect
SARS-CoV-2 infection were age, gender and region of origin in Spain’s autonomies. Despite
the lack of evidence that autoimmune diseases affect the risk of infection, we cannot
completely discard a possible bias caused by the autoimmune status of cases. However, we
assume a negligible effect caused by this possible bias in comparison with the other matching
parameters such as sex, age and place of residence, that have allowed us to obtain a large and
representative N of the different population groups. Finally, we lack information about chloro-
quine or hydroxychloroquine treatment doses for each subject what, in case of low doses could
not be enough to show an effect in the prevention of COVID-19. However, based on the Span-
ish Agency for Medicines and Health Products, the standard treatment for autoimmune dis-
eases such as lupus or rheumatoid arthritis usually ranges from 200 to 600mg of
hydroxychloroquine per day, what is in line with the dose given as a treatment to COVID-19
patients. Thus, the doses taken regularly by the subjects of the study and the doses used as
treatment for infected patients should not differ significantly what makes us think that this
should not represent a major limitation of our study.
However, our results are in line with a recent study conducting a randomized trial that
reported no effect of hydroxychloroquine when used as a post exposure prophylaxis for
COVID-19 [15].
Conclusion
All these data together point towards a lack of a protective effect of chloroquine or derivative
drugs as a prophylaxis for COVID-19, including prophylactic treatment before and after expo-
sure in patients with autoimmune diseases or other chronic conditions that require these treat-
ments, and potentially increase the risk for SARS-CoV-2 infection per se. Of relevance, data
indicates that people that regularly take chloroquine derivatives are exposed to SARS-CoV-2
infection and must take the same protection measures as the general population. These data
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should be considered in the prevention and treatment protocols made by health policymakers
for the management of the disease in new outbreaks. Finally, efficacy of chloroquine and its
derivatives in preventing SARS-CoV-2 infection will be determined by upcoming clinical
trials.
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